- Home
- DNTH vs CTO Comparison
DNTH vs CTO Comparison
Compare DNTH & CTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- CTO
- Stock Information
- Founded
- DNTH 2015
- CTO 1902
- Country
- DNTH United States
- CTO United States
- Employees
- DNTH N/A
- CTO N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- CTO Real Estate Investment Trusts
- Sector
- DNTH Health Care
- CTO Real Estate
- Exchange
- DNTH Nasdaq
- CTO Nasdaq
- Market Cap
- DNTH 568.6M
- CTO 589.6M
- IPO Year
- DNTH N/A
- CTO N/A
- Fundamental
- Price
- DNTH $18.85
- CTO $17.69
- Analyst Decision
- DNTH Strong Buy
- CTO Strong Buy
- Analyst Count
- DNTH 8
- CTO 3
- Target Price
- DNTH $53.00
- CTO $22.33
- AVG Volume (30 Days)
- DNTH 315.6K
- CTO 372.4K
- Earning Date
- DNTH 08-07-2025
- CTO 07-29-2025
- Dividend Yield
- DNTH N/A
- CTO 8.59%
- EPS Growth
- DNTH N/A
- CTO N/A
- EPS
- DNTH N/A
- CTO N/A
- Revenue
- DNTH $6,524,000.00
- CTO $132,203,000.00
- Revenue This Year
- DNTH N/A
- CTO $20.11
- Revenue Next Year
- DNTH N/A
- CTO $8.51
- P/E Ratio
- DNTH N/A
- CTO N/A
- Revenue Growth
- DNTH 102.36
- CTO 17.48
- 52 Week Low
- DNTH $13.37
- CTO $16.12
- 52 Week High
- DNTH $32.27
- CTO $21.15
- Technical
- Relative Strength Index (RSI)
- DNTH 54.07
- CTO 45.36
- Support Level
- DNTH $17.27
- CTO $17.10
- Resistance Level
- DNTH $19.46
- CTO $17.71
- Average True Range (ATR)
- DNTH 1.07
- CTO 0.37
- MACD
- DNTH 0.15
- CTO -0.05
- Stochastic Oscillator
- DNTH 76.74
- CTO 53.80
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.